newsfilter
← Latest News
Business Wire·

New England Journal of Medicine Publishes Pivotal Trial Data for OMONTYS® (peginesatide) Injection for Treatment of Anemia in Adult Chronic Kidney Disease Patients on Hemodialysis

PALO ALTO, Calif. & DEERFIELD, Ill.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) today announced that pivotal Phase 3 data on the safety and efficacy of OMONTYS® (peginesatide) Injection were published in the January 24th issue the New England Journal of Medicine (NEJM). These studies, known as EMERALD 1 and 2, compared OMONTYS given once monthly to epoetin administered one-to-three times per week (according to epoetin product labeling) in the treatment of anemia in adult chronic kidney disease (CKD) patients on hemodialysis.